Rallybio Corp

RLYBSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1739410

Concept	FY2024	FY2023	FY2022	FY2021
Revenues	$600.0K	—	—	—
Research and Development Expense	$53.5M	$40.7M	$26.9M	$17.6M
Operating Expenses	$78.9M	$67.9M	$45.6M	$25.3M
Operating Income (Loss)	-$78.9M	-$67.9M	-$45.6M	-$25.3M
Interest Expense	—	—	$10.0K	$49.0K
Nonoperating Income (Expense)	$6.4M	$2.3M	$140.0K	$363.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	-$45.5M	-$24.9M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	-$15.0K
Net Income (Loss) Attributable to Parent	-$74.6M	-$66.7M	-$47.0M	-$26.4M
Earnings Per Share, Basic	-$1.84	-$2.09

Concept	FY2024	FY2023	FY2022	FY2021
Assets	$115.6M	$180.4M	$182.2M	$141.9M
Assets, Current	$114.8M	$179.5M	$180.9M	$141.3M
Cash and Cash Equivalents, at Carrying Value	$24.5M	$57.0M	$175.3M	$140.2M
Liabilities	$9.4M	$11.1M	$6.6M	$5.9M
Liabilities, Current	$9.3M	$10.7M	$6.6M	$5.8M
Accounts Payable, Current	$976.0K	$1.1M	$603.0K	$1.6M
Stockholders' Equity Attributable to Parent	$169.3M	$175.6M	$136.0M	$16.9M
Common Stock, Shares, Outstanding	$37.8M	$37.8M	$32.1M	$23.4M

Concept	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$60.3M	-$57.3M	-$45.5M	-$22.0M
Net Cash Provided by (Used in) Investing Activities	$27.7M	-$112.2M	-$2.3M	-$2.1M
Net Cash Provided by (Used in) Financing Activities	$143.0K	$51.1M	$83.0M	$144.9M
Payments to Acquire Property, Plant, and Equipment	$12.0K	$54.0K	$333.0K	$137.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)